类风湿关节炎临床前期的EB病毒抗体应答提示病毒再激活周期增加
本研究纳入83例符合1987年ACR标准的RA患者和83例年龄、性别、种族匹配的无RA对照,检测临床前后血清中5种抗EBV抗体、7种RA相关自身抗体等。随机森林分析显示临床前IgG-EA抗体可区分RA与对照,RA患者IgG-EA水平高于对照,且临床前IgG-EA升高与IgM-RF升高显著相关。结论提示临床前EBV再激活周期增加,RF与EBV再激活组合可能参与RA发生。
要点
- 临床前IgG-EA抗体水平升高可区分日后发展为RA者与对照。
- RA患者临床前IgG-EA升高与IgM-RF升高显著相关。
- IgG-CMV抗体水平在组间无差异。
核心结论
- 临床前IgG-EA抗体升高的个体最终会发展为RA,提示RA临床前期EBV再激活周期增加。
- RF与EBV再激活的组合可能在RA发生中起重要作用。
研究设计与样本
- 纳入83例符合1987年ACR标准的RA患者和83例年龄、性别、种族匹配的无RA对照。
- 收集RA患者和匹配对照在RA诊断前和诊断后的血清,检测5种抗EBV抗体、7种RA相关自身抗体、22种细胞因子/趋化因子、36种抗瓜氨酸化蛋白抗体和IgG-CMV抗体。
- 采用随机森林分类、混合模型和联合混合模型分析抗EBV抗体水平差异。
主要发现
- 随机森林分析识别出临床前EBV抗体可区分RA患者与无RA对照。
- RA患者IgG-EA抗体水平(均值±SD 0.82±0.72 ISR)高于对照(均值±SD 0.49±0.28 ISR)。
- 在RA患者中,血清学转换前临床前期的IgG-EA水平升高与血清IgM-RF水平升高显著相关(P=0.007),而对照中未见此相关(P=0.15)。
- IgG-CMV抗体水平在组间无差异。
临床怎么用
- 临床前IgG-EA抗体升高可能提示EBV再激活周期增加,结合RF可帮助识别RA发生风险较高的个体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with established rheumatoid arthritis (RA) demonstrate altered immune responses to Epstein-Barr virus (EBV), but the presence and roles of EBV have not been fully explored during the pre-clinical disease period. This study was undertaken to determine if EBV infection, as evidenced by an altered anti-EBV antibody response, either plays an important role in driving the development of RA or is a result of expanded RA-related autoimmunity. METHODS: A total of 83 subjects with RA according to the 1987 American College of Rheumatology (ACR) criteria and 83 age-, sex-, and race-matched control subjects without RA were included in our study. We collected sera from RA subjects and matched controls during the pre-RA and post-RA diagnosis periods and tested the sera for the presence of 5 anti-EBV antibodies (anti-EBV nuclear antigen 1 IgG isotype, anti-viral capsid antigen [anti-VCA] isotypes IgG and IgA, and anti-early antigen [EA] isotypes IgG and IgA), 7 RA-related autoantibodies (rheumatoid factor measured by nephelometry [RF-Neph] as well as isotype-specific IgA-RF, IgM-RF, and IgG-RF, and anti-cyclic citrullinated peptide [anti-CCP] antibodies, including anti-CCP2, anti-CCP3, and anti-CCP3.1), 22 cytokines/chemokines, 36 individual anti-citrullinated protein antibodies, and IgG-cytomegalovirus (CMV) antibodies. Random forest classification, mixed modeling, and joint mixed modeling were used to determine differences in anti-EBV antibody levels between RA subjects and controls. RESULTS: Random forest analysis identified the presence of preclinical EBV antibodies in the serum that differentiated RA subjects from controls without RA. Specifically, IgG-EA antibody levels were higher in RA subjects (mean ± SD 0.82 ± 0.72 international standardized ratio [ISR]) compared to controls (mean ± SD 0.49 ± 0.28 ISR). In subjects with RA, elevated serum IgG-EA levels in the preclinical period before seroconversion were significantly correlated with increased serum IgM-RF levels (P = 0.007), whereas this correlation was not seen in control subjects without RA (P = 0.15). IgG-CMV antibody levels did not differ between groups. CONCLUSION: Subjects whose serum IgG-EA antibody levels are elevated in the preclinical period will eventually develop RA, which suggests that EBV reactivation cycles are increased during the preclinical period of RA. A combination of RF and EBV reactivation may play an important role in the development of RA.
引用
- Fechtner S, Berens H, Bemis E, et al. Antibody Responses to Epstein-Barr Virus in the Preclinical Period of Rheumatoid Arthritis Suggest the Presence of Increased Viral Reactivation Cycles. Arthritis Rheumatol. 2022. PMID: 34605217. doi:10.1002/art.41994
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。